Why Aurora Cannabis’s (ACB) Stock Price Fell 16% in December

Aurora Cannabis Inc. (TSX:ACB)(NYSE:ACB) stock price continues to fall, as the cannabis industry remains in disarray.

| More on:
Marijuana plant and cannabis oil bottles isolated

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

Cannabis stocks like Aurora Cannabis (TSX:ACB)(NYSE:ACB) had their heads handed to them in December once again, as the downward spiral continues.  When a bubble bursts, it falls hard, and Aurora Cannabis’s stock price is a prime example of this. Down 16% in December, 65% in the last year, and 81% from its highs, Aurora Cannabis stock still carries too much risk and uncertainty for investors.

So, why did Aurora Cannabis’s stock price fall again in December, and what, if anything, should investors do at this point?

Aurora Cannabis still reeling from disappointing results

The first quarter of fiscal 2020 turned out to be another disappointing quarter, as revenue growth continued to slow and as losses continued to mount. Revenue declined 24% sequentially in the quarter, as medical cannabis revenue increased a mere 3%, and Canadian consumer cannabis revenue declined 33%, as distribution and regulatory headwinds played havoc on the cannabis industry.

As per the company’s release, “provincial ordering slowed considerably during the summer as distributors worked through inventories and as the industry was impacted by the slow pace of retail store licensing.”

Executive shakeup amid high inventory levels

As the company moves forward, it has been making changes at the top. Chief Corporate Officer Cam Battley was asked to step down from his role at the company, as Aurora Cannabis and the industry in general tries to recover and move forward from the carnage brought about by excessive inventory levels and “weaker-than-expected” market growth.

The focus now will be on strengthening the balance sheet and cutting capital expenditures to a more sustainable level that takes into consideration the financial health (or lack thereof) of the business.

The bursting of a bubble

I have repeatedly warned fellow Fool investors that investing in the cannabis sector when many of the cannabis stocks were trading at multiples of north of 100 times sales was more of a gamble than an investment, that the stocks had reached bubble territory, and that it was only a matter of time before the bubble burst.

In December, Aurora Cannabis’s stock price continued to plummet, as the bursting of the bubble continued. There will be a time when these cannabis stocks represent value — an attractive risk/reward tradeoff — but the time in not now, as there remains much uncertainty and big downside in these growth stocks.

Earnings estimates for Aurora Cannabis stock have been slashed quite dramatically over the last year. The 2022 estimate was cut from $0.34 earlier this year to the current consensus estimate calling for a net loss of $0.01 per share.

Foolish final thoughts

The one silver lining here is that Aurora Cannabis stock price is now trading at a price-to-sales multiple of eight times. It is pretty much out of crazy bubble territory. It will take time for the stock recover, and it is still a very risky investment, but at least Aurora Cannabis has more than $2 billion in cash to take it through the upcoming tumultuous months.

Finally, I would like to remind Foolish investors of our belief in holding great businesses for the long term. While this belief remains intact, we are also aware that, sometimes, short-term stock price movements create opportunities to create wealth. By blending this long-term focus with a keen eye for short-term stock mispricings, we can use both strategies in harmony, and our quest for financial freedom can be fulfilled.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Karen Thomas has no position in any of the stocks mentioned.

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »